Online inquiry

IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2864MR)

This product GTTS-WQ2864MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2864MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10332MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ11948MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ14344MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ13628MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ13142MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ7534MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ5240MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ15979MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW